AKT1 and lymphoma: In addition, the evaluation of combinations with other targeted therapies, such as inhibitors of the PI3K/AKT pathway or CD20 signaling, and the assessment of the synergistic impact with immunotherapy, given its growing relevance in lymphoma, will be integral to our ongoing investigations.